06:26 AM EST, 03/08/2024 (MT Newswires) -- Unicycive Therapeutics ( UNCY ) said Thursday it has completed patient enrollment in a pivotal clinical trial for Oxylanthanum Carbonate for the potential treatment of hyperphosphatemia in patients with chronic kidney disease.

The company expects topline data from the trial in Q2.

The primary endpoint for the trial will evaluate the tolerability of clinically effective doses of Oxylanthanum Carbonate in patients with chronic kidney disease on dialysis. The secondary endpoints seeks to evaluate safety and pharmacokinetics.

Price: 1.38, Change: -0.12, Percent Change: -8